The number of people suffering from psoriasis, who have also developed chronic inflammatory arthritis, is increasing. This is making psoriasis a serious problem. Chronic arthritis may also result in disabilities and joint deformations, and thus psoriasis needs to be treated quickly. Systemic therapies, which has been introduced few years ago is boosting the global psoriasis market. However, this form of therapy cannot be provided to patients with existing kidney and liver diseases and pregnant and nursing women. Thus, there is a need for new therapies which is safe and can be effectively used on all patients, and this is creating opportunities for growth in the market. Geographically, North America, followed by Europe is leading in the psoriasis market. The rising incidences of psoriasis among people in these regions are driving the market. Some of the leading players operating in the psoriasis market include: Celgene Corporation, Johnson & Johnson, Novartis International AG, AbbVie, Pfizer Inc., AMGen, Eli Lilly and Company, LEO Pharma A/S, Merck & Co., Inc., and Can-Fite Biopharma Inc.